article
14 September 2016 | By Dr Norman Peterson (MedImmune/AstraZeneca)
As advances in protein engineering technology have led to the production of novel and more structurally complex biopharmaceuticals, the ability of these drugs to smoothly traverse the body and arrive at their intended target site has become more unpredictable...